BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/25/2018 2:53:56 AM | Browse: 1129 | Download: 1973
 |
Received |
|
2018-09-13 02:54 |
|
Peer-Review Started |
|
2018-09-13 12:50 |
|
To Make the First Decision |
|
2018-10-08 03:40 |
|
Return for Revision |
|
2018-10-09 10:16 |
|
Revised |
|
2018-10-20 03:47 |
|
Second Decision |
|
2018-11-14 11:19 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2018-11-16 05:57 |
|
Articles in Press |
|
2018-11-16 05:57 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2018-11-27 01:41 |
|
Typeset the Manuscript |
|
2018-12-13 04:27 |
|
Publish the Manuscript Online |
|
2018-12-25 02:53 |
| ISSN |
1948-0210 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Cell Biology |
| Manuscript Type |
Minireviews |
| Article Title |
Cancer stem cell impact on clinical oncology
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Mariel Esperanza Toledo-Guzmán, Gabriele D Bigoni-Ordóñez, Miguel Ibáñez-Hernández and Elizabeth Ortiz-Sanchez |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Elizabeth Ortiz-Sanchez, MD, PhD, Academic Research, Professor, Research Scientist, Senior Researcher, Subdirección de Investigación Básica, Instituto Nacional de Cancerología, Av San Fernando 22, Colonia Sección XVI, Mexico City 14080, Mexico. elinfkb@yahoo.com.mx |
| Key Words |
Cancer; Targeted therapy; Clinical outcome; Drug resistance; Cancer stem cells |
| Core Tip |
Tumor heterogeneity can explain the presence of cells that display high tumorigenic capacity along with chemo- and radio-resistance properties. These cells, identified as cancer stem cells (CSCs), are partially responsible for recurrence and tumor progression. Most tumors follow the CSC model, which indicates the existence of a subset of highly tumorigenic cells. This has been shown to be the case for several patients with several types of tumors. In this review, we focus on the phenotypes used for the study and identification of CSCs from human samples, as well as promising strategies to target CSCs. |
| Publish Date |
2018-12-25 02:53 |
| Citation |
Toledo-Guzmán ME, Bigoni-Ordóñez GD, Ibáñez Hernández M, Ortiz-Sánchez E. Cancer stem cell impact on clinical oncology. World J Stem Cells 2018; 10(12): 183-195 |
| URL |
https://www.wjgnet.com/1948-0210/full/v10/i12/183.htm |
| DOI |
https://dx.doi.org/10.4252/wjsc.v10.i12.183 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
